Acutaas Chemicals Ltd
ACUTAASAcutaas Chemicals Ltd's price has outrun its earnings. +187.9% in a year against EPS +124.5% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +187.9% in a year while annual EPS moved +124.5% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (110 weeks in) while the P/E sits at the 86th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +112.7% year on year, and 95% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Acutaas Chemicals Ltd trades at ₹3,284, in a confirmed uptrend and 110 weeks into that stage. That is +59.8% against its own 200-day average. It sits at 100% of a 52-week range of ₹1,105 to ₹3,284. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 44 straight weeks.
Today the stock is in a confirmed uptrend — week 110 of stage 2, confirmed. At ₹3,284 it trades +59.8% versus its 200-day average and sits at 100% of its 52-week range (₹1,105–₹3,284).
Against the market, two honest reads. Cumulative: over the last 4.7 years the stock moved +441% while the NIFTY 500 moved +50% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 44 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 86th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Acutaas Chemicals Ltd trades at 75.2× P/E, at the pricey end of its own range (86th percentile). Its long-run median P/E is 58.9×, measured across 4.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 75.2× is at the pricey end of its own range (86th percentile), against a long-run median of 58.9× measured over 4.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +124.5% against a +187.9% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +75.6%/yr price move, ~+56.1%/yr came from earnings growth and ~+19.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 22% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Acutaas Chemicals Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 8 quarters ago at −18.2% and has held its recovery at +112.7% (single-quarter readings), ROCE lifting at 32.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +33.0% | +29.5% | +31.5% | — |
| Profit | +122.5% | +62.5% | +45.8% | — |
| EPS | +124.5% | +56.1% | +38.4% | — |
| Share price | +187.9% | +75.6% | — | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
No sector-relative score — Acutaas Chemicals Ltd is not present in the sector comparison for Pharma - API & CRAMS.
The score is a rank WITHIN a peer set: every metric is scored by percentile against the other members. Without the peer set there is no score to state, so none is invented here.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Acutaas Chemicals Ltd reported ₹433 Cr of revenue in the Mar 26 quarter, +40.6% year on year. That is the 10th straight quarter of year-on-year growth. Over 9 years it has compounded at 26.6% a year. The last full year, FY26, came in at ₹1,339 Cr. The last four reported quarters add to ₹1,339 Cr.
Acutaas Chemicals Ltd reported ₹433 Cr of revenue in the Mar 26 quarter, +40.6% year on year. That is the 10th straight quarter of year-on-year growth. Over 9 years it has compounded at 26.6% a year. The last full year, FY26, came in at ₹1,339 Cr. The last four reported quarters add to ₹1,339 Cr.
FY26 revenue came in at ₹1,339 Cr (+33.0% on the year), capping 9 years at 26.6% compound. The latest quarter (Mar 26) printed ₹433 Cr, +40.6% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +31.1% growth against the decade's 26.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +33.0% over the last 4 quarters against +36.7%/yr over the last 8 — rolling over; TTM profit +121.1% vs +169.5%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 42.0% this quarter (+14.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Acutaas Chemicals Ltd's operating margin is 42.0% in the Mar 26 quarter, +14.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 10 fiscal years the operating margin has ranged 14.0% to 36.0%. The current quarter is running above every full year in that window.
Acutaas Chemicals Ltd's operating margin is 42.0% in the Mar 26 quarter, +14.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 10 fiscal years the operating margin has ranged 14.0% to 36.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 42.0%, +14.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 14.0%–36.0%, and FY26's 36.0% is the top of that band — a record year.
Why the margin moved: operating margin went +14.9 pp year on year while gross margin went +14.7 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins held — did that reach the bottom line? Next: profit +112.7% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Acutaas Chemicals Ltd earned ₹134 Cr of net profit in the Mar 26 quarter, +112.7% year on year. It is the 6th consecutive quarter of growth. Full-year FY26 profit was ₹356 Cr. The 9-year compound rate is 45.7%. That is 30.9% of the quarter's revenue. The same quarter a year earlier earned ₹63.0 Cr.
Acutaas Chemicals Ltd earned ₹134 Cr of net profit in the Mar 26 quarter, +112.7% year on year. It is the 6th consecutive quarter of growth. Full-year FY26 profit was ₹356 Cr. The 9-year compound rate is 45.7%. That is 30.9% of the quarter's revenue. The same quarter a year earlier earned ₹63.0 Cr.
Mar 26 profit was ₹134 Cr, +112.7% year on year — the 6th consecutive quarter of growth. On the full year, FY26 printed ₹356 Cr (+122.5%), and the 9-year compound rate is 45.7%.
Why profit moved: revenue contributed +40.6% and the margin +14.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +132.8% vs revenue +31.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 95% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 95% of Acutaas Chemicals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹292 Cr of operating cash against ₹356 Cr of profit. After ₹413 Cr of capital spending, ₹−121 Cr was left as free cash.
FY26: operating cash of ₹292 Cr against reported profit of ₹356 Cr, leaving free cash of ₹−121 Cr after ₹413 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 95% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 95%: the cash cycle stretched 69 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 11.0× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹867 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Acutaas Chemicals Ltd's cash conversion cycle runs 149 days in FY26, up from 80 days in FY21. Capital spending ran ₹867 Cr over the last 3 years. At FY26 sales of ₹1,339 Cr each day of that cycle holds about ₹3.7 Cr, so roughly ₹547 Cr sits inside the business at any moment.
FY26: debtors at 99 days, inventory at 149 days — roughly 4.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 149 days, looser than FY21's 80.
The full loop: cash goes out to suppliers and production on day 0; stock waits 149 days to sell; customers pay about 99 days after that; and suppliers themselves are paid at 99 days — netting out to the 149-day cycle.
In money terms: at FY26 sales of ₹1,339 Cr, each day of the cycle holds about ₹3.7 Cr — so the 149-day loop keeps roughly ₹547 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹867 Cr over the last 3 fiscal years against ₹79.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹332 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 32%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Acutaas Chemicals Ltd earns a ROCE of 32% in FY26. That is up from a trough of 16% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 26.6% net margin on 0.67× asset turns.
FY26 ROCE is 32%, recovered from a FY24 trough of 16% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 26.6% net margin × 0.67× asset turns × 1.20× balance-sheet leverage ≈ 21.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 22% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.02.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Acutaas Chemicals Ltd carries ₹36.0 Cr of borrowings against ₹1,654 Cr of equity in FY26, a debt-to-equity of 0.02. Operating profit covers the interest bill north of 100×. Over 5 years borrowings went from ₹137 Cr to ₹36.0 Cr. Capital spending ran ₹867 Cr across the last 3 of those years.
FY26: borrowings of ₹36.0 Cr against equity of ₹1,654 Cr — a debt-to-equity of 0.02. Operating profit covers the interest bill north of 100×. Over 5 years borrowings went from ₹137 Cr to ₹36.0 Cr while capital spending ran ₹867 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 22% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 12.8 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 12.8 points of Acutaas Chemicals Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 19.6% of the company. Foreign institutions moved +10.5 points over the same window, to 19.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +12.8 points over 8 quarters to 19.6%; Foreign institutions: +10.5 points over 8 quarters to 19.5%; Promoters: −7.3 points over 8 quarters to 32.7%.
Why the register moved: domestic institutions drove it (+12.8 points), alongside foreign institutions (+10.5 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Acutaas Chemicals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Acutaas Chemicals Ltd this page | 75.2× | ₹26,785 Cr | Improving | |||
| Divis Laboratories Ltd | 73.4× | ₹1.9L Cr | Mixed | |||
| Laurus Labs Ltd | 79.1× | ₹86,505 Cr | Mixed | |||
| Anthem Biosciences Ltd | 73.1× | ₹43,360 Cr | No read | |||
| Gland Pharma Ltd | 37.6× | ₹39,257 Cr | Improving | |||
| Acutaas Chemicals Ltd | 69.1× | ₹26,686 Cr | Mixed | |||
| Sai Life Sciences Ltd | 73.8× | ₹26,174 Cr | No read | |||
| Piramal Pharma Ltd | — | ₹24,133 Cr | No read | |||
| Neuland Laboratories Ltd | 65.9× | ₹23,794 Cr | Turning around | |||
| Granules India Ltd | 31.8× | ₹20,655 Cr | Consistent | |||
| OneSource Specialty Pharma Ltd | — | ₹18,961 Cr | No read | |||
| Syngene International Ltd | 44.9× | ₹16,708 Cr | Turning around | |||
| Syngene International Ltd | 44.1× | ₹16,415 Cr | Turning around | |||
| Cohance Lifesciences Ltd | 80.9× | ₹15,957 Cr | Deteriorating | |||
| Jubilant Pharmova Ltd | 35.2× | ₹15,378 Cr | No read | |||
| Concord Biotech Ltd | 54.8× | ₹13,061 Cr | Deteriorating | |||
| Shilpa Medicare Ltd | 50.8× | ₹11,856 Cr | No read | |||
| Blue Jet Healthcare Ltd | 43.3× | ₹10,730 Cr | Deteriorating | |||
| Supriya Lifescience Ltd | 32.3× | ₹6,765 Cr | Consistent | |||
| IOL Chemicals & Pharmaceuticals Ltd | 30.0× | ₹4,380 Cr | Improving | |||
| SMS Pharmaceuticals Ltd | 35.0× | ₹3,569 Cr | Mixed | |||
| Morepen Laboratories Ltd | 39.6× | ₹2,948 Cr | Mixed | |||
| Dishman Carbogen Amcis Ltd | 29.0× | ₹2,878 Cr | No read | |||
| Hikal Ltd | 73.8× | ₹2,681 Cr | Deteriorating | |||
| Solara Active Pharma Sciences Ltd | 551.0× | ₹2,351 Cr | No read | |||
| Windlas Biotech Ltd | 26.6× | ₹1,770 Cr | Mixed |
Frequently asked questions
What is Acutaas Chemicals Ltd's share price today?
Acutaas Chemicals Ltd trades at ₹3,284, +187.9% over the past year. The company is valued at ₹26,785 Cr. The stock sits at 100% of its 52-week range of ₹1,105–₹3,284, +59.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 110 weeks in. — as of 24 July 2026.
What were Acutaas Chemicals Ltd's latest quarterly results?
Acutaas Chemicals Ltd reported revenue of ₹433 Cr and net profit of ₹134 Cr for the Mar 26 quarter. Revenue rose 40.6% and profit rose 112.7% year on year. Earnings per share were ₹16.09. The operating margin was 42.0%, 14.0 pp higher than a year earlier. — as of 24 July 2026.
What is Acutaas Chemicals Ltd's revenue?
Acutaas Chemicals Ltd reported revenue of ₹433 Cr in the Mar 26 quarter, +40.6% year on year. For the full FY26 fiscal year, revenue was ₹1,339 Cr (+33.0%). Over the last 9 years revenue compounded at 26.6% a year. — as of 24 July 2026.
What is Acutaas Chemicals Ltd's profit?
Acutaas Chemicals Ltd earned ₹134 Cr of net profit in the Mar 26 quarter, +112.7% year on year — the 6th straight quarter of growth. Full-year FY26 profit was ₹356 Cr. The operating margin ran 42.0% in the latest quarter. — as of 24 July 2026.
What is Acutaas Chemicals Ltd's market cap?
Acutaas Chemicals Ltd's market capitalisation is ₹26,785 Cr at a share price of ₹3,284. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Acutaas Chemicals Ltd's P/E ratio?
Acutaas Chemicals Ltd trades at a P/E of 75.2×, at the 86th percentile of its own 5-year range, against a long-run median of 58.9×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Acutaas Chemicals Ltd pay a dividend?
Yes — Acutaas Chemicals Ltd's dividend payout was 6% of profit in FY26, and it recorded a payout in 5 of its last 10 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Acutaas Chemicals Ltd overvalued?
On its own history, Acutaas Chemicals Ltd looks expensive against its own history: its P/E of 75.2× sits at the 86th percentile of its 5-year range (long-run median 58.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is Acutaas Chemicals Ltd growing?
Yes — Acutaas Chemicals Ltd is growing: latest-quarter revenue +40.6% year on year, profit +112.7%, and the margin +14.0 pp at 42.0%. The 9-year compound rates are 26.6% (revenue) and 45.7% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Acutaas Chemicals Ltd performing?
Acutaas Chemicals Ltd is in a confirmed uptrend, 110 weeks in. Its latest quarter's revenue rose 40.6% and profit rose 112.7% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 44 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Acutaas Chemicals Ltd in?
Improving — profit growth bottomed 8 quarters ago at −18.2% and has held its recovery at +112.7% (single-quarter readings), ROCE lifting at 32.0%. The read comes from the last 12 quarters of growth (revenue growth +40.6% latest, profit growth +112.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Acutaas Chemicals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 110 of stage 2), trading +59.8% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Acutaas Chemicals Ltd beating the market?
On recent form, yes — Acutaas Chemicals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 44 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 4.7 years the stock moved +441% against the NIFTY 500's +50% — ahead of the index over the full window. — as of 24 July 2026.
Will Acutaas Chemicals Ltd's share price go up?
This page publishes no price forecast for Acutaas Chemicals Ltd. What it measures instead: the share price is ₹3,284, the price is in a confirmed uptrend 110 weeks in. Its P/E of 75.2× sits at the 86th percentile of its own 5-year range. — as of 24 July 2026.
Who owns Acutaas Chemicals Ltd?
Promoters hold 32.7% of Acutaas Chemicals Ltd, foreign institutions 19.5%, domestic institutions 19.6% and the public 28.2% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 12.8 points over 8 quarters. — as of 24 July 2026.
Does Acutaas Chemicals Ltd have too much debt?
No — Acutaas Chemicals Ltd's debt-to-equity is 0.02, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹36.0 Cr against equity of ₹1,654 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Acutaas Chemicals Ltd's capex?
Acutaas Chemicals Ltd spent ₹867 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹413 Cr, with ₹332 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Acutaas Chemicals Ltd's cash flow?
Acutaas Chemicals Ltd generated ₹292 Cr of operating cash flow in FY26 and ₹−121 Cr of free cash flow after ₹413 Cr of capital spending. Reported profit that year was ₹356 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Acutaas Chemicals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 95% of Acutaas Chemicals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹292 Cr against reported profit of ₹356 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Acutaas Chemicals Ltd in its business cycle?
Acutaas Chemicals Ltd's FY26 operating margin was 36.0%, against a 10-year band of 14.0%–36.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 42.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Acutaas Chemicals Ltd story?
The sharpest disagreement: the price moved +187.9% in a year while annual EPS moved +124.5% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Acutaas Chemicals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Acutaas Chemicals Ltd's price has outrun its earnings. +187.9% in a year against EPS +124.5% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.